Shanghai Rendu Biotechnology Co. Ltd. A

Rendu Bio released its 2026 interim report. Net profit attributable to the parent for the first half was 9.58 million yuan, up 369.9% year-on-year. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 4.28 million yuan in the same period last year to a profit of 1.37 million yuan. First-half operating revenue was 79.44 million yuan, down 2.2% year-on-year. Net operating cash flow was negative 2.05 million yuan, down 97.2% year-on-year. Earnings per share were 0.239 yuan. In the second quarter, operating revenue was 37.36 million yuan, down 7.9% year-on-year. Net profit attributable to the parent was 4.58 million yuan, up 460.6% year-on-year, and the loss in net profit attributable to the parent after deducting non-recurring items narrowed. As of the end of the second quarter, total assets were 948 million yuan, down 4.2% from the end of the previous year. Net assets attributable to the parent were 884 million yuan, down 3.3% from the end of the previous year. The company continued to focus on RNA isothermal amplification technology, launched multiple new products in the molecular diagnostics reagent field, and drove profit growth through cost reduction and efficiency improvement measures.

First-half 2026 reports from in vitro diagnostics companies listed on the STAR Market show sharp divergence, with Autobio Diagnostics, Biotest Biotech and Orient Gene posting lower net profit while Rendu Biotechnology saw a surge. Autobio Diagnostics' first-half revenue and net profit fell 8.77% and 61.48% respectively, to 392 million yuan and 51 million yuan. Second-quarter revenue and net profit dropped 11.11% and 55.58% year on year, which the company attributed to intensifying industry competition, foreign exchange losses and higher research and development expenses. Orient Gene and Biotest Biotech grew revenue but not profit. Orient Gene's net loss widened to 222 million yuan, down 36.26% year on year, while Biotest Biotech swung from profit to a loss of 16.55 million yuan, plunging 233.46% year on year. Both cited US dollar exchange losses. Rendu Biotechnology's revenue edged down 2.22% to 79.44 million yuan, but net profit attributable to the parent surged 369.86% year on year to 9.58 million yuan, and non-recurring net profit turned positive, mainly thanks to cost reduction and efficiency gains. Selling, administrative and research and development expenses fell 11.86%, 10.10% and 21.98% respectively. In addition, companies such as YHLO Biotech, HOB Biotech and Dian Diagnostics also achieved net profit growth, with Dian Diagnostics' net profit soaring 2,160% to 232 million yuan. However, for some companies the improvement in profit was driven mainly by cost reduction and efficiency gains and a narrowing of credit impairment losses. The industry remains in a deep adjustment cycle, with centralised procurement, medical insurance cost controls and exchange rate fluctuations continuing to affect corporate performance.

The medical device sector rebounded in afternoon trading, with Biolight hitting the 20% daily limit up. Earlier, Chaoyan Medical rose by the daily limit, Aohua Endoscopy gained over 10%, and Apon Medical, Rendu Biotechnology, Haitex, Nanwei Medical, and Lude Medical also followed the upward trend. The General Office of the Zhejiang Provincial People's Government issued several measures this morning to promote industry-academia-research collaboration in brain-computer interfaces, aiming for future industry revenue from brain-computer interfaces to exceed 5 billion yuan by 2027, and to establish a globally competitive hub for brain-computer interface technology and industry innovation by 2030.